ACAD

27.74

0.22% 0.06

Dopo l'orario di chiusura: 27.74

Acadia Pharmaceuticals Inc (ACAD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ACAD Giù? Forum Previsione

Precedente Chiudi:

$27.68

Aprire:

$27.63

Volume 24 ore:

1.01M

Relative Volume:

0.63

Capitalizzazione di mercato:

$4.78B

Reddito:

$1.10B

Utile/perdita netta:

$375.65M

Rapporto P/E:

12.63

EPS:

2.1963

Flusso di cassa netto:

$113.59M

1 W Prestazione:

-0.43%

1M Prestazione:

-5.61%

6M Prestazione:

+23.07%

1 anno Prestazione:

+16.55%

Intervallo 1D:

$27.36

$27.86

Intervallo di 1 settimana:

$27.10

$28.19

Portata 52W:

$19.69

$30.96

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Nome

Acadia Pharmaceuticals Inc

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

858-558-2871

Indirizzo

12830 EL CAMINO REAL, SAN DIEGO

Dipendente

798

Cinguettio

@acadiapharma

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

ACAD's Discussions on Twitter

Compare ACAD vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ACAD Acadia Pharmaceuticals Inc	27.74	4.77B	1.10B	375.65M	113.59M	2.1963
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-25	Aggiornamento	BofA Securities	Neutral → Buy
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-02-23	Aggiornamento	Mizuho	Neutral → Outperform
2025-10-21	Iniziato	Citigroup	Buy
2025-05-21	Aggiornamento	Deutsche Bank	Hold → Buy
2025-02-11	Iniziato	Deutsche Bank	Hold
2025-01-03	Downgrade	Guggenheim	Buy → Neutral
2024-10-10	Ripresa	Raymond James	Mkt Perform
2024-08-07	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-06-27	Iniziato	BMO Capital Markets	Outperform
2024-03-12	Downgrade	Mizuho	Buy → Neutral
2024-03-12	Reiterato	Needham	Buy
2024-01-30	Iniziato	Robert W. Baird	Outperform
2024-01-24	Aggiornamento	Needham	Hold → Buy
2023-12-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Downgrade	Deutsche Bank	Buy → Hold
2023-12-13	Iniziato	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-06	Aggiornamento	Mizuho	Neutral → Buy
2023-10-17	Iniziato	UBS	Buy
2023-10-10	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-11-04	Downgrade	Goldman	Neutral → Sell
2022-11-01	Iniziato	Loop Capital	Hold
2022-08-08	Downgrade	Citigroup	Buy → Neutral
2022-08-05	Downgrade	Citigroup	Buy → Neutral
2022-06-21	Downgrade	Jefferies	Buy → Underperform
2022-06-16	Aggiornamento	Jefferies	Hold → Buy
2022-03-16	Aggiornamento	Canaccord Genuity	Hold → Buy
2022-02-09	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-01-05	Aggiornamento	Citigroup	Neutral → Buy
2021-12-21	Downgrade	Guggenheim	Buy → Neutral
2021-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-06-10	Iniziato	Berenberg	Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-04-06	Downgrade	Goldman	Buy → Neutral
2021-04-06	Downgrade	Jefferies	Buy → Hold
2021-04-06	Downgrade	Mizuho	Buy → Neutral
2021-04-05	Downgrade	Raymond James	Outperform → Mkt Perform
2021-03-10	Downgrade	BofA Securities	Buy → Neutral
2021-03-09	Downgrade	Citigroup	Buy → Neutral
2021-03-09	Downgrade	Guggenheim	Buy → Neutral
2021-03-09	Reiterato	H.C. Wainwright	Buy
2021-03-09	Downgrade	Raymond James	Strong Buy → Outperform
2021-03-09	Downgrade	Stifel	Buy → Hold
2020-12-16	Iniziato	Mizuho	Buy
2020-11-16	Aggiornamento	Raymond James	Outperform → Strong Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Iniziato	Morgan Stanley	Overweight
2020-07-07	Aggiornamento	Stifel	Hold → Buy
2020-04-16	Iniziato	Jefferies	Buy
2020-03-31	Aggiornamento	Goldman	Neutral → Buy
2020-03-06	Iniziato	Citigroup	Buy
2019-12-16	Iniziato	Guggenheim	Buy
2019-10-24	Iniziato	Oppenheimer	Perform
2019-10-01	Iniziato	RBC Capital Mkts	Outperform
2019-09-13	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Aggiornamento	Canaccord Genuity	Hold → Buy
2019-07-23	Reiterato	Needham	Buy
2018-12-10	Iniziato	Canaccord Genuity	Hold
2018-09-21	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-08-09	Reiterato	Stifel	Hold
2018-08-07	Iniziato	Stifel	Hold
2018-08-06	Downgrade	Piper Jaffray	Overweight → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

Sep 09, 2026

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits

Sep 09, 2026

Avoiding Lag: Real-Time Signals in (ACAD) Movement - Stock Traders Daily

Sep 09, 2026

Sep 08, 2026

ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits

Sep 08, 2026

Sep 05, 2026

Acadia Pharma GLP-1 Receptor Agonists Weight Management Diabetes Treatments zLHGd49l0 - akhmetovfoundation.org

Sep 05, 2026

Sep 04, 2026

Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Sep 04, 2026

Sep 03, 2026

Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com India

Sep 03, 2026

Aug 31, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains As Fundamentals Improve - Kalkine Media

Aug 31, 2026

Aug 29, 2026

The Technical Signals Behind (ACAD) That Institutions Follow - Stock Traders Daily

Aug 29, 2026

Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative? - Sahm

Aug 29, 2026

Aug 26, 2026

Is ACADIA Pharmaceuticals (ACAD) Still Trading At A Discount As DAYBU Wins EU Approval? - Sahm

Aug 26, 2026

Aug 25, 2026

Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38 - Moomoo

Aug 25, 2026

Deutsche Bank raises Acadia Pharma price target after EU approval of Daybu for Rett syndrome. - Pluang

Aug 25, 2026

Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Aug 25, 2026

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40 - Moomoo

Aug 25, 2026

Aug 24, 2026

Acadia Gets European Commission Nod for Daybu in Rett Syndrome - Eastern Progress

Aug 24, 2026

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe - pharmaphorum

Aug 24, 2026

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union - Via TT

Aug 24, 2026

Aug 21, 2026

ACADIA (ACAD) Close: Advances 1.05% to $29.34; Technical View: the Session Ends Within the Reported Technical Boundaries on the DayMarket Leader Picks - vinanet.vn

Aug 21, 2026

Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 21, 2026

Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 21, 2026

ACADIA (ACAD) Financial Results: Reported EPS Tops Expectations for the Current Session; Market Response - vinanet.vn

Aug 21, 2026

Aug 19, 2026

ACADIA (ACAD) Earnings Report: EPS Clears the Reported Estimate at the Close; Closing Reaction: The Stock Gains 1.09% in the Current UpdateSlow Growth Warning - vinanet.vn

Aug 19, 2026

Aug 18, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media

Aug 18, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat

Aug 18, 2026

BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36 - Moomoo

Aug 18, 2026

Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 18, 2026

UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49 - Moomoo

Aug 18, 2026

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st

Aug 18, 2026

Aug 17, 2026

UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia

Aug 17, 2026

ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus

Aug 17, 2026

UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com

Aug 17, 2026

GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 17, 2026

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 17, 2026

Aug 16, 2026

48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat

Aug 16, 2026

Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 16, 2026

Aug 15, 2026

Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 15, 2026

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView

Aug 15, 2026

Aug 13, 2026

STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus

Aug 13, 2026